Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide Expanded Access for Hepatic Veno-occlusive Disease
2017-004316-18Phase 3
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2017
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of defibrotide in hepatic veno-occlusive disease (HVOD), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Survival at Day +100.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on 2017-004316-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004316-18.